JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Home・Akcijų sąrašas・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

33.46 -2.16

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

33.1

Max

34.68

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-14M -81M
Pardavimai	75K 75K
Pelnas, tenkantis vienai akcijai	-1.22
Pelno marža	-108,422.667
Darbuotojai	198
EBITDA	-7.8M -81M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+65.45% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1.1B 2.7B
Ankstesnė atidarymo kaina	35.62
Ankstesnė uždarymo kaina	33.46

Naujienos nuotaikos

By Acuity

50%

179 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

18.91 / 20.63 Palaikymas ir pasipriešinimas

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-23 00:00; UTC

Svarbiausios naujienos

Australian Flash PMI Bounce in April Conceals Deeper Worries

2026-04-22 23:33; UTC

Uždarbis

SK Hynix Posts Record Quarterly Results Amid AI Boom

2026-04-22 22:40; UTC

Uždarbis

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

2026-04-22 22:10; UTC

Įsigijimai, susijungimai, perėmimai

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

2026-04-22 21:11; UTC

Uždarbis

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

2026-04-22 21:01; UTC

Uždarbis

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

2026-04-22 23:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-22 23:46; UTC

Rinkos pokalbiai

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

2026-04-22 23:34; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

2026-04-22 23:16; UTC

Uždarbis

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

2026-04-22 23:15; UTC

Uždarbis

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

2026-04-22 22:54; UTC

Uždarbis

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

2026-04-22 22:54; UTC

Uždarbis

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

2026-04-22 22:52; UTC

Uždarbis

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

2026-04-22 22:51; UTC

Uždarbis

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

2026-04-22 22:31; UTC

Uždarbis

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

2026-04-22 22:31; UTC

Uždarbis

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

2026-04-22 22:30; UTC

Uždarbis

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

2026-04-22 22:30; UTC

Uždarbis

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

2026-04-22 22:29; UTC

Uždarbis

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

2026-04-22 22:28; UTC

Uždarbis

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

2026-04-22 22:28; UTC

Uždarbis

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

2026-04-22 22:27; UTC

Uždarbis

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

2026-04-22 22:06; UTC

Rinkos pokalbiai

Uždarbis

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

2026-04-22 21:55; UTC

Įsigijimai, susijungimai, perėmimai

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

2026-04-22 21:47; UTC

Uždarbis

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026-04-22 21:37; UTC

Uždarbis

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

2026-04-22 21:34; UTC

Uždarbis

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

2026-04-22 21:29; UTC

Uždarbis

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026-04-22 21:20; UTC

Rinkos pokalbiai

Uždarbis

Tesla Expands Manufacturing to Chips -- Market Talk

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

65.45% į viršų

12 mėnesių prognozė

Vidutinis 56.6 USD 65.45%

Aukščiausias 90 USD

Žemiausias 34 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Celldex Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

179 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.